Menopausal Hormone Therapy Does Not Increase Mortality

Why It Matters

The results dispel lingering safety fears, supporting broader clinical use of MHT and informing policy decisions that affect millions of menopausal women and related healthcare costs.

Key Takeaways

• Study of 800k Danish women found no mortality increase
• 12% used MHT, median duration 1.7 years
• No rise in cardiovascular or cancer deaths observed
• Bilateral oophorectomy patients showed 27‑34% lower mortality
• Findings reinforce Endocrine Society and RCOG hormone guidelines

Pulse Analysis

Menopause marks a pivotal physiological transition, often accompanied by vasomotor symptoms, mood changes, and heightened cardiovascular risk. Since the early 2000s, the Women’s Health Initiative sparked widespread caution about menopausal hormone therapy (MHT) due to reported increases in breast cancer and thrombotic events. However, those trials primarily involved older women well beyond the typical onset of menopause, leaving a knowledge gap for younger, perimenopausal patients seeking symptom relief and potential health‑span benefits.

The new Danish cohort leverages nationwide registers to track more than 800,000 women from age 45 onward, providing an unprecedented sample size and follow‑up of up to 21 years. Approximately one‑tenth of the cohort used MHT, predominantly oral estradiol formulations, for a short median duration. Statistical models, including sibling comparisons to control for familial confounders, revealed no increase in all‑cause mortality, cardiovascular death, or cancer mortality. Notably, women who underwent bilateral oophorectomy and used MHT experienced a striking 27‑34% reduction in mortality, suggesting a protective effect when endogenous estrogen is abruptly lost.

These findings carry immediate implications for clinicians and policymakers. By confirming the safety profile of short‑term MHT and highlighting benefits for oophorectomy patients, the study reinforces existing guidelines from the Endocrine Society and the Royal College of Obstetricians and Gynaecologists. Health systems can confidently prescribe MHT to alleviate severe menopausal symptoms without fearing elevated mortality risk, potentially reducing menopause‑related workforce attrition and associated economic losses. Future research should explore optimal dosing routes, such as transdermal gels, and longer‑term outcomes to fine‑tune individualized therapy strategies.